A protocol for a systematic review and meta-analysis of fractional dose compared to standard dose inactivated polio vaccination in children. 
Strengths and Limitations of the study
We developed this protocol following the PRISMA-P guidelines and will report the review following PRISMA guidelines.
We will conduct study selection, data extraction, and risk of bias assessment in duplicate; resolving discrepancies by discussion, consensus, and arbitration.
We will use the GRADE approach to evaluate the certainty of the evidence for each outcome.
We plan to include non-randomised studies, which are prone to having a high risk of selection bias. However, we plan to mitigate this limitation by conducting sensitivity analyses to assess the robustness of the findings to study design. 
INTRODUCTION
Poliomyelitis (or polio) is a communicable disease caused by one of three related wild polioviruses: poliovirus types 1, 2 and 3. Polio attacks at any age but mainly affects children under five. [1] The virus typically enters the body through the mouth and multiplies inside the gut. Initially it manifests as flu-like symptoms. Once established, it enters the bloodstream and attacks the central nervous system. As it proliferates, it destroys nerve cells which stimulate muscles. These nerve cells cannot be renewed and affected muscles no longer function; causing paralysis. The virus circulates silently at first, possibly infecting up to 200 people before the first case of paralysis surfaces. Immunity against polio comes from either natural infection, which is when one recovers from polio or is immunised against contracting the disease through vaccination. There are two polio vaccines which are highly effective. The first is an injectable vaccine developed in the 1950s (the inactivated polio vaccine) and the second an oral vaccine developed in the 1960s (the oral polio vaccine). [1] Before the introduction of mass vaccination against polio, millions of children died or suffered from permanent disability worldwide. [2] The widespread use of the oral polio vaccine (OPV) resulted in substantial advances towards eradicating polio. [2] [3] [4] However, the vaccine has been associated with vaccine associated paralytic poliomyelitis (VAPP) and the generation of vaccine derived polioviruses (VDPVs). [5, 6] These liabilities threaten the achievement of a polio free world. The Polio Eradication and Endgame Strategic Plan 2013-2018 outlines the necessary steps required to ensure that transmission of both wild polio viruses (WPV) and VDPVs is interrupted. One of its objectives is to prevent spread and re-emergence of VDPVs by gradually replacing OPV with inactivated polio vaccine (IPV). [7] The first stage in the phased removal of OPV was completed in April 2016. [8] It involved the cessation of the type 2 component of OPV through a global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV). [7] Prior to switching, in November 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended the introduction of at least one dose of IPV in immunisation schedules to mitigate the risk of re-introduction or re-emergence of WPV type 2 or VDPV type 2. [9] This dose was meant to provide an immune base to improve immunological reactions and lower the risk of paralysis in the event of a type 2 polio outbreak. [2, 10] In its 2016 polio vaccine position paper, the World Health Organisation (WHO) endorsed the recommendation. [2] Subsequently, the demand for IPV increased globally from 80 million doses in 2013 to 200 million doses in 2016. [11] The global manufacturers that had assured the Global Polio Eradication Initiative (GPEI) and its partners about the feasibility of scaling up production to meet the demand, only managed to supply about half of the required doses for 2016 and 2017 and the supply is deteriorating. [11, 12] With the limited supply and lack of competition in the market, the cost of IPV (up to US$ 2.8 per dose) [12, 13] further restricts access.
IPV shortages and high cost have given rise to delayed IPV introduction in some countries, while countries that have IPV as part of their schedule experience stock outs. [14, 15] By September 2016, about 105 out of 126 countries that had OPV-only immunisation schedules had introduced IPV. [16] According to an update from UNICEF in March 2017, there are 18 countries that have introduced IPV which will only receive IPV shipments in the first half of 2018. [17] Going forward, after the expected certification of global polio eradication in 2022, IPV will be the only vaccine being used. [18] This puts pressure on both the global community and individual countries to come up with strategies to ensure affordable and reliable long-term supply of IPV. To address the current shortages and ensure availability of IPV, GPEI and its partners are using a multipronged approach. [15] One of the recommended strategies is the use of dose sparing fractional doses instead of a full dose of IPV. [2, 15] One fractional dose (0.1ml) is one fifth of the full dose (0.5 ml) and it is usually delivered using an intradermal injection. Several randomised studies have assessed the immunogenicity of two fractional doses of IPV (fIPV) compared to one full dose of IPV. [19] [20] [21] [22] Vaccination invokes a humoral immune response producing antibodies which guarantee a life-long protection against polio viruses.
[2] Intradermal delivery of the polio vaccine is an efficient and effective mode of vaccination because it allows for the dose sparing approach. [23, 24] Due to the abundance of immune cells in the dermis, when a vaccine is given via the dermis, a lower dose can be used compared to the intramuscular and subcutaneous routes. [24] Though an intramuscular full dose of IPV results in a better immunogenicity than a single fractional intradermal dose, after two fractional doses immunogenicity can be equal or even higher than that of a single full dose. [2] In terms of cost, the price of one fifth of the dose is expected to be a fifth of the price of the full dose; hence reducing the cost. [3] According to an assessment that was done by PATH, two fIPV doses and the intradermal injection devices cost between US$1 to US$3 while a single intramuscular dose of IPV costs between US$ 1.1 and US$2.3. [24] This dose sparing strategy might be the immediate solution to ensure that every child who is entitled to receive IPV is vaccinated. India and Sri-Lanka have already introduced the two fIPV doses in their routine immunisation schedules with notable successes. In both countries, they have managed to immunise a larger number of eligible children while stretching their stocks; subsequently avoiding stock outs. [15] A mass vaccination campaign using a single fIPV was successfully carried out in response to a VDPV type 2 outbreak in the Telangana State of India in May 2016. [25] Each country is encouraged to consider the programmatic and logistic challenges that come with introducing fIPV before rolling out the policy. [2] Intradermal administration involves purchasing of devices to administer, training health workers and other logistics which affect the feasibility of the programme. [16] Programmes in India and Sri Lanka have demonstrated that despite these challenges, a nationwide programme using fIPV is possible even in an outbreak setting. [15, 25] The Sustainable Development Goal number 3 includes achieving access to affordable, safe and effective essential vaccines for all by 2030. [26] Replacing OPV with IPV is essential for the eradication of indigenous polio and VAPP. As we progress towards the certification of the global eradication of polio, ensuring sustainable, reliable and affordable IPV supply is of paramount importance. The dose sparing and cost reduction characteristics of fractionated doses can contribute to improved IPV access. Two reviews have been done to inform decisions regarding fractionated IPV dosages therefore there is a need for more evidence.
Grassly [27] performed a systematic review and meta-analysis to assess the immunogenicity and effectiveness of 1 or 2 doses of fIPV in routine immunisation. The author found that two fIPV doses administered after 10 weeks of age are likely to provide 80% protection against poliomyelitis. It is now 5-6 years since the literature search was conducted for this review, and new evidence has accumulated since then. [22, 25] In addition, study selection and data extraction were not done in duplicate; increasing the risk of systematic errors in this timely review. [27] It is an indispensable practice in systematic reviews to conduct those steps in duplicate, and resolve discrepancies by discussion and consensus or arbitration. [28] F o r p e e r r e v i e w o n l y
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In another review, Anand et al [10] focused on comparing immunogenicity of two fIPV and one full dose of IPV. They concluded that two fIPV doses are more immunogenic than a single dose. Of note, in both reviews [10, 27] , there is absence of an extensive search of the literature. Grassly searched only the Web of Knowledge collection of databases and Anand and colleagues' search was restricted to the PubMed database only. Therefore, there might be other studies that were excluded from these reviews that may alter their findings. Vaccine safety and administration are important considerations when deciding on an immunisation schedule. In both reviews, there is dearth of information about the adverse effects of different IPV dosages and the devices used to give the intradermal injections. In addition, none of the previous reviews used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method [29] to assess the certainty of the evidence on effects of fIPV.
We aim to do a systematic review of studies comparing the effects of fractional compared to full dose IPV vaccination. We will evaluate the occurrence of adverse events and types of administration devices used for the intradermal delivery of fIPV.
OBJECTIVES
The objective of this review is to assess the effects of fractional doses of inactivated polio vaccine, compared a full dose of the vaccine.
METHODS AND ANALYSIS
Criteria for considering studies for this review Types of studies We will include randomised trials, non-randomised trials, case-control studies, cohort studies, and other non-randomised studies of interventions.
Types of Participants
The participants of interest will be children aged five years of age or younger.
Types of intervention
Our intervention is fractional dosing of IPV (in one or more doses), given via the intradermal or other routes of administration. The fractional doses of IPV can be given in combination with an OPV immunisation schedule or an IPV only schedule. This intervention will be compared to a full dose of IPV given via the intramuscular or other routes of administration. In eligible studies where there are multiple interventions, we will include pair-wise comparisons that address the objectives of the review as outlined above. To avoid double counts when analysing correlated groups, we will pool the groups together to create a single pair-wise comparison. [30] Types of outcome measures The primary outcome for this review is immunogenicity (as defined by the authors of the included studies). We will be looking for the number of children who seroconverted for wild poliovirus types 1, 2, 3. In addition to the seroconversion rates, we will extract geometric mean (or median) titres of antibodies for wild poliovirus serotypes 1, 2, and 3. Our secondary outcomes include adverse events following immunisation; vaccine associated paralytic polio; and wild poliovirus associated paralytic polio. We will also describe the routes and devices used to administer the fractional doses of the vaccine.
Search methods for identification of studies
We will develop a comprehensive search strategy for peer-reviewed and grey literature. We will search the following databases from the inception to the date of the search; with no date or publication restrictions: Cochrane 
Selection of studies
Two authors will independently screen the titles and abstracts of all records retrieved from the search, for potentially eligible studies. We will obtain full-texts for all the potential eligible studies. Two authors will assess these full-text publications for eligibility. We plan to translate full-texts of potentially eligible studies which are not written in English before assessing for eligibility. Any disagreements between the two authors regarding study eligibility will be resolved by discussion and consensus. A third author will arbitrate any unresolved disagreements. We will provide a table with the characteristics of the included studies, and another of excluded studies with reasons for their exclusion. We will seek additional information, for studies with missing information, to assist us in our decision-making process.
Data extraction and management
For each included study, two authors will independently extract information using a piloted data extraction form. Extracted data will include study, participant, intervention, and outcome characteristics as well as outcome data. Any differences will be resolved through discussion and consensus. A third author will be consulted to arbitrate if disagreements persist between the two authors. If there are missing data, we will contact study investigators for the missing information.
Assessment of risk and bias in included studies
Two authors will independently assess the risk of bias for each included study using the Cochrane Risk of Bias tool for trials, [31] the ROBINS-I tool non-randomised studies of interventions. [32] For trials, we will assess the risk of bias across seven domains: random sequence generation, allocation concealment, blinding of participants and study personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other potential source of bias. To 8 measure the quality of each study, whether trial or not, we will categorise our risk of bias judgements as low, high, or unclear bias. Differences in judgement will be resolved by discussion and consensus, or arbitration by a third author.
Dealing with missing data
For incomplete or missing data, we will contact corresponding authors to request additional information or clarification. Missing data and dropouts will be reported in the 'Risk of bias' table and we will evaluate the impact of missing data on our results. Where possible we will conduct intention to treat analysis (ITT). We will conduct sensitivity analyses were by missing data is treated as successes or failures (worst-best and best-worst case scenario sensitivity analysis).
Data Synthesis
We will use the risk ratio (RR) and its corresponding 95% confidence interval to summarise binary data. For continuous data, we will calculate the mean difference (MD) and its 95% confidence interval when the outcome data is measured on the same scale. Alternatively, if the measurement scale differs, the standardised mean difference (SMD) and its 95% confidence interval will be used. For studies with similar participant, interventions, outcomes, and study designs, we will pool the study data using the random-effect method of meta-analysis.
Assessment of heterogeneity
Initially we will assess for heterogeneity by visually inspecting the forest plots for overlapping confidence intervals. To further evaluate statistical heterogeneity, we use the χ 2 test of homogeneity; with significance defined at the alpha level of 10. We will also use the I 2 statistic to quantify the amount of heterogeneity. [33] We will investigate the causes of statistical heterogeneity using subgroup analyses. We will define subgroups based on the timing of the first fractional dose, age of administration, number of fractional doses, interval between doses, poliovirus type (1, 2 and 3), type of intradermal injection device, immunisation schedules, and country income status. [34] Assessment of reporting biases We will reduce possible publication bias by using a comprehensive search strategy. Literature sources will include published, unpublished, and grey literature. To investigate possible publication bias, we will construct funnel plots if there are more than 10 studies included in the metaanalysis. [35] Sensitivity analysis We will perform sensitivity analyses to assess if the effect of fIPV will be affected by of bias (by excluding studies with a high risk of data), study designs (randomised versus non-randomised), and methods of meta-analysis (fixed versus random effects).
Reporting Review Findings
We have written this protocol, and we will report the outcome, following the recommendations of relevant PRISMA guidelines. [35] [36] [37] Additionally, forest plots GRADE summary of findings tables will be used to report the outcome of our analysis. We will use the GRADE approach to evaluate the certainty of the evidence. The approach assesses the certainty of a body of evidence as high, moderate, low, or very low; through evaluating the risk of bias, imprecision, inconsistency and indirectness of study results, and the risk of publication bias. [38, 39] ETHICS AND DISSEMMINATION Collection of data for our review does not involve direct contact with human participants. Instead will use published and publicly accessed data. For this reason, we did not seek ethical approval. The protocol outline will be published in the PROSPERO International Prospective Register of Systematic 
ABSTRACT Introduction
The WHO recommends the introduction of at least one single dose of inactivated polio vaccine (IPV) in routine immunisation schedules. Thus, there has been an increased demand and concurrent supply shortages of IPV worldwide. One of the strategies to improve access is the use of fractional instead of full doses of IPV. We aim to compare the effects of fractional to standard doses of IPV.
Methods and Analysis
We will include randomised trials, non-randomised trials, case-control studies, and cohort studies that compared fractional to full doses of IPV among children aged five years or younger. We will search for eligible studies among published and grey literature. Two authors will independently screen the results of the search, select studies, extract data and assess risk of bias. We will stratify analyses by study design, type of poliovirus, type of outcome measure, and number of IPV doses given. For each type of poliovirus, we will pool the outcome data from studies using random-effects meta-analyses. Statistical heterogeneity will be assessed using the χ 2 test of homogeneity and quantified using the I 2 statistic. To investigate heterogeneity, subgroup analysis will be performed based on the timing of the first fractional dose, age of administration, immunisation schedules, and country income status. Sensitivity analyses will be used to assess if the effect of IPV fractional dosing is affected by study design, risk of bias, and methods of meta-analysis.
Ethics and dissemination
We obtained approval from the University of Cape Town Human Research Ethics Committee (HREC REF: 412/2018). The findings of this review will provide evidence for decision-making with regards to IPV dosage eventually improving access to the vaccine by stretching vaccine supplies. The results will be published in the University of Cape Town online library and in a peer reviewed journal.
PROSPERO protocol registration number: CRD42018092647
Key words Inactivated polio vaccine, fractional dosing, dose-sparing, polio eradication, vaccine shortage 
Strengths and Limitations of the study
 We developed this protocol following the PRISMA-P guidelines and will report the review following PRISMA guidelines.
 We will conduct study selection, data extraction, and risk of bias assessment in duplicate;
resolving discrepancies by discussion, consensus, and arbitration.
 We will use the GRADE approach to evaluate the certainty of the evidence for each outcome.
 We plan to include non-randomised studies, which are prone to having a high risk of selection bias. However, we plan to mitigate this limitation by conducting sensitivity analyses to assess the robustness of the findings to study design. The virus typically enters the body through the mouth and multiplies inside the gut. Initially it manifests as flu-like symptoms. Once established, it enters the bloodstream and attacks the central nervous system. As it proliferates, it destroys nerve cells which stimulate muscles. These nerve cells cannot be renewed and affected muscles no longer function; causing paralysis. Up to 95% of infected individuals are asymptomatic and about 5% who develop minor flu-like symptoms fully recover. [2] Paralysis occurs in less than 1% of infected individuals. [2] Immunity against polio comes from either natural infection, which is when one recovers from polio or is immunised against contracting the disease through vaccination. There are two polio vaccines which are highly effective. The first is an injectable vaccine developed in the 1950s (the inactivated polio vaccine) and the second an oral vaccine developed in the 1960s (the oral polio vaccine). [1] In the early 1980s, more than 350 000 cases of paralytic polio were estimated to occur per year worldwide. [3] The widespread use of the oral polio vaccine (OPV) resulted in substantial advances towards eradicating polio. [3] [4] [5] However, the vaccine has been associated with vaccine associated paralytic poliomyelitis (VAPP) and the generation of vaccine derived polioviruses (VDPVs). [6, 7] These liabilities threaten the achievement of a polio free world. The Polio Eradication and Endgame Strategic Plan 2013-2018 outlines the necessary steps required to ensure that transmission of both wild polio viruses (WPV) and VDPVs is interrupted. One of its objectives is to prevent spread and reemergence of VDPVs by gradually replacing OPV with the inactivated polio vaccine (IPV). [8] The first stage in the phased removal of OPV was completed in April 2016. [9] It involved the cessation of the type 2 component of OPV through a global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV). [8] Prior to switching, in November 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended the introduction of at least one dose of IPV in national immunisation schedules to mitigate the risk of re-introduction or re-emergence of WPV type 2 or VDPV type 2. [10] This dose was meant to provide an immune base to improve immunological reactions and lower the risk of paralysis in the event of a type 2 polio outbreak. [3, 11] In its 2016 polio vaccine position paper, the World Health Organisation (WHO) endorsed the recommendation. [3] Globally, the demand for IPV increased from 80 million doses in 2013 to 200 million doses in 2016.
[12] The global manufacturers that had assured the Global Polio Eradication Initiative (GPEI) and its partners about the feasibility of scaling up production to meet the demand, only managed to supply about half of the required doses for 2016 and 2017 and the supply is deteriorating. [12, 13] With the limited supply and lack of competition in the market, the cost of IPV (up to US$ 2.8 per dose) [13, 14] further restricts access in resource-constrained countries.
IPV shortages and high cost have given rise to delayed IPV introduction in some countries, while countries that already have IPV as part of their schedule are experiencing stock outs. [15, 16] By September 2016, about 105 out of 126 countries that had OPV-only immunisation schedules had introduced IPV. [17] According to an update from UNICEF in March 2017, there were 18 countries that had introduced IPV which were only to receive IPV shipments in the first half of 2018. [18] Going forward, after the expected certification of global polio eradication in 2022, IPV will be the only vaccine being used. [19] This puts pressure on both the global community and individual countries to come up with strategies to ensure affordable and reliable long-term supply of IPV. To address the current shortages and ensure availability of IPV, the GPEI and its partners are using a multipronged approach. [16] One of the recommended strategies is the use of dose sparing fractional doses instead of full doses of IPV. [3, 16] One fractional dose (0.1ml) is one fifth of the full dose (0.5 ml) and it is usually delivered using an intradermal injection. Several randomised studies have assessed the immunogenicity of fractional doses of IPV (fIPV) compared to full dose(s) of IPV. [20] [21] [22] [23] Vaccination invokes a humoral immune response producing antibodies which, in most cases, offer long term protection against polio viruses.
[3] Intradermal delivery of the polio vaccine is an efficient and effective mode of vaccination because it allows for the dose sparing approach. [24, 25] Due to the abundance of immune cells in the dermis, when a vaccine is given via the dermis, a lower dose can be used compared to the intramuscular and subcutaneous routes. [25] In terms of cost, the price of one fifth of the dose is expected to be a fifth of the price of the full dose; hence reducing the cost. [4] According to an assessment that was done by PATH, two fIPV doses and the intradermal injection devices cost between US$1 to US$3 while a single intramuscular dose of IPV costs between US$ 1.1 and US$2.3. [25] This dose sparing strategy might be the immediate solution to ensure that every child who is entitled to receive IPV is vaccinated. India and Sri Lanka have already introduced the fIPV doses in their routine immunisation schedules with notable successes. In both countries, they have managed to vaccinate a larger number of eligible children while stretching their stocks; subsequently avoiding stock outs. [16] A mass vaccination campaign using a single fIPV was successfully carried out in response to a VDPV type 2 outbreak in the Telangana State of India in May 2016. [26] Countries are encouraged to consider the programmatic and logistic challenges that come with introducing fIPV before rolling out the policy. [3] Intradermal administration involves purchasing of devices to administer, training health workers and other logistics which affect the feasibility of the programme. [17] Programmes in India and Sri Lanka have demonstrated that despite these challenges, a nationwide programme using fIPV is possible even in an outbreak setting. [16, 26] The Sustainable Development Goal number 3 includes achieving access to affordable, safe and effective vaccines for all by 2030. [27] Replacing OPV with IPV is essential for the eradication of WPV and VAPP. As we progress towards the certification of the global eradication of polio, ensuring sustainable, reliable and affordable IPV supply is of paramount importance. The dose sparing and cost reduction characteristics of fractionated doses can contribute to improved IPV access. This review will add to the evidence gathered by other reviews to inform decisions regarding the value of fractionated IPV dosages.
Grassly [28] performed a systematic review and meta-analysis to assess the immunogenicity and effectiveness of 1 or 2 doses of fIPV in routine immunisation. The author found that two fIPV doses administered after 10 weeks of age are likely to provide 80% protection against poliomyelitis. It is now 5-6 years since the literature search was conducted for this review, and new evidence has accumulated since then. [23, 26] In addition, study selection and data extraction were not done in duplicate; increasing the risk of systematic errors in this timely review. [28] It is an indispensable practice in systematic reviews to conduct those steps in duplicate, and resolve discrepancies by discussion and consensus or arbitration. [29] In another review, Anand et al. [11] focused on comparing immunogenicity of two fIPV and one full dose of IPV. They concluded that two fIPV doses are more immunogenic than a single dose. Of note, in both reviews [11, 28] , there is absence of an extensive search of the literature. Grassly searched only the Web of Knowledge collection of databases and Anand and colleagues' search was restricted to the PubMed database only. Therefore, there might be other studies that were excluded from these reviews that may alter their findings. Vaccine safety and administration are important considerations when deciding on an immunisation schedule. The previous reviews did not evaluate adverse effects of different IPV dosages and the devices used to give the intradermal injections. In addition, none of the previous reviews used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method [30] to assess the certainty of the evidence on effects of fIPV.
We aim to do a systematic review of studies comparing the effects of fractional compared to full dose IPV vaccination. We will evaluate the occurrence of adverse events and document the types of administration devices used for the intradermal delivery of fIPV.
OBJECTIVES
The objective of this review is to assess the effects of fractional doses of inactivated polio vaccine, compared full doses of the vaccine.
METHODS AND ANALYSIS
Criteria for considering studies for this review Types of studies We will include randomised trials, non-randomised trials, case-control studies and cohort studies.
Types of participants
Types of intervention
The eligible intervention will be the administration of fractional dose(s) of IPV, while the eligible comparison will be the administration of full dose(s) of the vaccine; irrespective of vaccination schedule or route of administration. We will also describe the routes and devices used to administer the fractional doses of the vaccine.
[31]
Types of outcome measures
The primary outcome for this review is immunogenicity, measured using the proportion of participants who sero-converted (as defined by the authors of the included studies). as well as titres of poliovirus-neutralising antibodies for wild poliovirus serotypes 1, 2, and 3; assessed at least four weeks following vaccination.
Our secondary outcomes include adverse events following polio vaccination; vaccine associated paralytic polio; and wild poliovirus associated paralytic polio and mucosal immunity (as defined by the authors). We will also describe the routes and devices used to administer the fractional doses of the vaccine.
Search methods for identification of studies
We will develop a comprehensive search strategy for peer-reviewed and grey literature. We will search the following databases from the inception to the date of the search; with no date or publication restrictions: Cochrane Central Register of Controlled Trials (CENTRAL), 
Selection of studies
Two authors (Thandiwe Mashunye and Kopano Dube) will independently screen the titles and abstracts of all studies considered by one or both authors as records retrieved from the search, for potentially eligible studies. We will obtain full-texts for all the potential eligible studies. The two authors will assess these full-text publications for eligibility. We plan to translate full-texts of potentially eligible studies which are not written in English before assessing for eligibility. Any disagreements between the two authors regarding study eligibility will be resolved by discussion and consensus. A third author (Duduzile Ndwandwe or Charles Wiysonge) will arbitrate any unresolved disagreements.
Data extraction and management
For each included study, two authors (Thandiwe Mashunye and Kopano Dube) will independently extract the information indicated in Table 1 using a pre-designed and piloted data extraction form. Extracted data will include study, participant, intervention, and outcome characteristics as well as study findings (Table 1) . We will present this information in a table of the characteristics of included studies. Any differences will be resolved through discussion and consensus between the two authors. A third author (Duduzile Ndwandwe or Charles Wiysonge) will be consulted to arbitrate if disagreements persist between the two authors. If there are missing data, we will contact study investigators for the missing information. 
Study design and methods
Citation information (authors, journal, year of publication, volume, issue, and page numbers); study design (randomised trial, non-randomised trial, case-control study, cohort study); study location (city, country), and period of study (start and end date i.e. month and year). Methods for generating randomisation sequence, concealing allocation of interventions, and blinding of outcome assessment; number of participants randomised and number with complete outcome data for each outcome; names of outcomes announced in study protocol but not reported in study publication, and other biases.
Participant characteristics
Age, sex, study location, study inclusion and exclusion criteria, flow of numbers of participants during the study (from participant enrolment to completion of data collection).
Intervention
Definition of fractional dose, manufacturer of vaccine, immunisation schedule (frequency, timing, interval between doses, etc), OPV coadministration, route of administration (intradermal, sub-cutaneous, etc), and types of devices used for administration of the fractional doses (name, manufacturing company, etc).
Comparison
Definition of full dose, manufacturer of vaccine, immunisation schedule (frequency, timing, interval between doses, etc), OPV co-administration, route of administration (intramuscular, sub-cutaneous, etc).
Outcome measures Outcomes reported in the study (immunogenicity, adverse events following polio vaccination, vaccine associated paralytic polio, wild poliovirus associated paralytic polio, mucosal immunity), how they were defined, and how they were measured.
Outcome data Seroconversion (number of participants randomised and number who seroconverted in each arm), antibody titres (geometric mean plus standard deviation or median and range in each arm), number of participants randomised and number who experienced the following events in each arm: adverse events following IPV vaccination, vaccine associated paralytic polio, wild poliovirus associated paralytic polio, mucosal immunity.
Assessment of risk and bias in included studies
Two authors will independently assess the risk of bias for each included study using the Cochrane Risk of Bias tool for trials [32] and the ROBINS-I tool non-randomised studies of interventions. [33] For trials, we will assess the risk of bias across seven domains: random sequence generation, allocation concealment, blinding of participants and study personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other potential source of bias. For each included study, whether trial or not, we will describe what the study authors reported that they did for each domain and then assign a judgement of low, high, or unclear risk of bias. Differences in judgement will be resolved by discussion and consensus, or arbitration by a third author. Based on these assessments, we will classify each included study as having a low, moderate, or high risk of bias. Each study that receives a judgement of high risk for allocation concealment, blinding of outcome assessment, or completeness of outcome data will be considered to have a high risk of bias. A study that is judged to have low risk of bias for all three domains will be considered to have a low risk of bias. All other studies will be considered to have a moderate risk of bias. We will use these risks of bias data in the GRADE assessments of certainty of evidence, as described below, by downgrading the certainty of the evidence of effects from trials with high risk of bias. Dealing with missing data For incomplete or missing data, we will contact corresponding authors to request additional information or clarification. Missing data and dropouts will be reported in the 'risk of bias' table and we will evaluate the impact of missing data on our results. Where possible we will conduct intention to treat analysis (ITT). We will conduct sensitivity analyses were by missing data is treated as successes or failures (worst-best and best-worst case scenario sensitivity analysis).
Data Synthesis
We will stratify the analyses by the type of study design, type of poliovirus, type of outcome measure, and number of IPV doses given. We will use the risk ratio (RR) and its corresponding 95% confidence interval to summarise data for the following binary outcome measures (seroconversion, adverse events following polio vaccination, vaccine associated paralytic polio, and wild poliovirus associated paralytic polio). For geometric median titres (our only outcome measure with continuous data), we will calculate the mean difference (MD) and its 95% confidence interval when the outcome data is measured on the same scale. Alternatively, if the measurement scale differs, the standardised mean difference (SMD) and its 95% confidence interval will be used.
For each type of poliovirus, we will pool the outcome data from studies with the same design and amount of IPV doses administered using the random-effect method of meta-analysis. In studies where there are multiple interventions, we will include pair-wise comparisons that address the objectives of our review as outlined above. To avoid double counts when analysing correlated groups, we will pool the groups together to create a single pair-wise comparison
Assessment of heterogeneity
Initially we will assess for heterogeneity by visually inspecting the forest plots for overlapping confidence intervals. To further evaluate statistical heterogeneity, we use the χ 2 test of homogeneity; with significance defined at the alpha level of 0.10. We will also use the I 2 statistic to quantify the amount of heterogeneity. [34] We will investigate the causes of statistical heterogeneity using subgroup analyses.
We will define subgroups based on the timing of the first fractional dose, age of administration, number of fractional doses, interval between doses, poliovirus type (1, 2 and 3), type of intradermal injection device, immunisation schedules (OPV containing versus non-OPV schedules), and country income status. [35] Assessment of reporting biases We will reduce possible publication bias by using a comprehensive search strategy. Literature sources will include published, unpublished, and grey literature. To investigate possible publication bias, we will construct funnel plots if there are more than 10 studies included in the metaanalysis. [36] Sensitivity analysis We will perform sensitivity analyses to assess if the effect of fIPV will be affected by of bias (by excluding studies with a high risk of data), study designs (randomised versus non-randomised), and methods of meta-analysis (fixed versus random effects).
Reporting review findings
We have written this protocol, and we will report the outcome, following the recommendations of relevant PRISMA guidelines. [37] [38] [39] Additionally, forest plots and GRADE summary of findings tables will be used to report the outcome of our analysis. We will use the GRADE approach to evaluate the certainty of the evidence.
The GRADE approach assesses the certainty of a body of evidence as high, moderate, low, or very low; through evaluating the risk of bias, imprecision, inconsistency and indirectness of study results, and the risk of publication bias. [40, 41] Regarding risk of bias, concerns that will limit our confidence in the evidence of effects are lack of allocation concealment, lack of blinding of outcome assessment, and differential losses to follow-up between intervention and comparison groups of more than 10%. Inconsistency of effects across included studies, for which we find no compelling explanations, will reduce our confidence in the evidence. Indirectness occurs when there are differences between the participants, interventions, comparisons, and outcomes of a review, and those reported in included studies. We do not anticipate that this will be an issue in our planned review. For imprecision, if we obtain pooled estimates of effects with wide confidence intervals (a situation which occurs when included studies have small number of participants and experience few events), we will rate down the certainty of the evidence. Finally, we will downgrade the certainty of evidence of effects of fIPV if our funnel plots show a high likelihood of publication bias.
Patient and public involvement
Patients were not involved in the design of this study.
ETHICS AND DISSEMMINATION
Collection of data for our review does not involve direct contact with human participants. Instead will use published and publicly accessed data. We obtained approval from 
ABSTRACT Introduction
The World Health Organisation recommends the introduction of at least one single dose of inactivated polio vaccine (IPV) in routine immunisation schedules. Thus, there has been an increased demand and concurrent supply shortages of IPV worldwide. One of the strategies to improve access is the use of fractional instead of full doses of IPV. We aim to compare the effects of fractional to standard doses of IPV.
Methods and Analysis
We will include randomised trials, non-randomised trials, case-control studies, and cohort studies that compared fractional to full doses of IPV among children aged five years or younger. We will search for eligible studies among published and grey literature. Two authors will independently screen the results of the search, select studies, extract data and assess risk of bias. We will stratify analyses by study design, type of poliovirus, type of outcome measure, and number of IPV doses given. For each type of poliovirus, we will pool the outcome data from studies using random-effects meta-analyses. Statistical heterogeneity will be assessed using the χ 2 test of homogeneity and quantified using the I 2 statistic. To investigate statistical heterogeneity, subgroup analyses will be performed based on the timing of the first fractional dose, age of administration, immunisation schedules, and country income status. Sensitivity analyses will be used to assess if the effect of IPV fractional dosing is affected by study design, risk of bias, and methods of meta-analysis.  We will use the GRADE approach to evaluate the certainty of the evidence for each outcome.
Ethics and dissemination
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INTRODUCTION
Poliomyelitis (or polio) is a communicable disease caused by one of three related wild polioviruses: poliovirus types 1, 2 and 3. Infection can occur at any age but it mainly affects children under five. [1] The virus typically enters the body through the mouth and multiplies inside the gut. Initially it manifests as flu-like symptoms. Once established, it enters the bloodstream and attacks the central nervous system. As it proliferates, it destroys nerve cells which stimulate muscles. These nerve cells cannot be renewed and affected muscles no longer function; causing paralysis. Up to 95% of infected individuals have no symptoms and about 5% who develop minor flu-like symptoms fully recover. [2] Paralysis occurs in less than 1% of infected individuals. [2] Immunity against polio is acquired following recovery from a natural infection with poliovirus or vaccination with a polio vaccine. There are two types of polio vaccines, which are highly effective. The first is an injectable vaccine developed in the 1950s (the inactivated polio vaccine) and the second an oral vaccine developed in the 1960s (the oral polio vaccine). [1] In the early 1980s, more than 350 000 cases of paralytic polio were estimated to occur per year worldwide. [3] The widespread use of the oral polio vaccine (OPV) resulted in substantial advances towards eradicating polio. [3] [4] [5] However, the vaccine has been linked to vaccine associated paralytic poliomyelitis (VAPP) and the generation of vaccine derived polioviruses (VDPVs). [6, 7] These liabilities threaten the achievement of a polio free world. The Polio Eradication and Endgame Strategic Plan 2013-2018 outlines the necessary steps required to ensure that transmission of both wild polio viruses (WPV) and VDPVs is interrupted. One of its objectives is to prevent the spread and re-emergence of VDPVs by gradually replacing OPV with the inactivated polio vaccine (IPV). [8] The first stage in the phased removal of OPV was completed in April 2016. [9] It involved the cessation of the type 2 component of OPV through a global switch from trivalent OPV (containing all three poliovirus types) to bivalent OPV (containing only poliovirus types 1 and 3). [8] Prior to switching, in November 2012, the Strategic Advisory Group of Experts on Immunisation (SAGE) recommended the introduction of at least one dose of IPV in national immunisation schedules to mitigate the risk of re-introduction or re-emergence of WPV type 2 or VDPV type 2. [10] This minimum dose was meant to provide an immune base to improve immune response and lower the risk of paralysis in the event of a type 2 polio outbreak. [3, 11] In its 2016 polio vaccine position paper, the World Health Organisation (WHO) endorsed the recommendation. [3] Globally, the demand for IPV increased from 80 million doses in 2013 to 200 million doses in 2016.
[12] The global manufacturers only managed to supply about half of the required doses for 2016 and 2017 and the supply is deteriorating. [12, 13] With the limited supply and lack of competition in the market, the cost of IPV (up to US$ 2.8 per dose) [13, 14] further restricts access in resource-constrained countries.
IPV shortages and high cost have given rise to delayed IPV introduction in some countries, while countries that already have IPV as part of their schedule are experiencing stock outs. [15, 16] By September 2016, about 105 out of 126 countries that had OPV-only immunisation schedules had introduced IPV. [17] According to an update from UNICEF in March 2017, there were 18 countries that had introduced IPV which were only to receive IPV shipments in the first half of 2018. [18] Going forward, after the expected certification of global polio eradication in 2022, IPV will be the only vaccine being used. [19] This puts pressure on both the global community and individual countries to come up with strategies to ensure affordable and reliable long-term supply of IPV. To address the current shortages and ensure availability of IPV, the GPEI and its partners are using a multipronged approach. [16] One of the recommended strategies is the use of dose sparing fractional doses instead of full doses of IPV. [3, 16] One fractional dose (0.1ml) is one fifth of the full dose (0.5 ml) and it is usually delivered using an intradermal injection. Several randomised studies have assessed the immunogenicity of fractional doses of IPV (fIPV) compared to full dose(s) of IPV. [20] [21] [22] [23] Polio vaccination invokes a humoral immune response producing antibodies which, in most cases, offer long term protection against polio viruses.
[3] Intradermal delivery of the polio vaccine is an efficient and effective mode of vaccination because it allows for the dose sparing approach. [24, 25] Due to the abundance of immune cells in the dermis, when a vaccine is given via the dermis, a lower dose can be used compared to the intramuscular and subcutaneous routes. [25] In terms of cost, the price of one fifth of the dose is expected to be a fifth of the price of the full dose; hence reducing the cost. [4] According to an assessment that was done by PATH, two fIPV doses and the intradermal injection devices cost between US$1 to US$3 while a single intramuscular dose of IPV costs between US$ 1.1 and US$2.3. [25] This dose sparing strategy might be the immediate solution to ensure that every child who is entitled to receive IPV is vaccinated. India and Sri Lanka (among other countries) have introduced the fIPV doses in their routine immunisation schedules with notable successes. Both countries have managed to vaccinate a larger number of eligible children while stretching their IPV vaccine stocks; subsequently avoiding stock outs. [16] A mass vaccination campaign using a single fIPV was successfully carried out in response to a VDPV type 2 outbreak in the Telangana State of India in May 2016. [26] Countries are encouraged to consider the programmatic and logistic challenges that come with introducing fIPV before rolling out the policy. [3] Intradermal administration involves purchasing of devices to administer, training health workers, and other logistics which affect the feasibility of the programme. [17] Programmes in India and Sri Lanka have demonstrated that despite these challenges, a nationwide programme using fIPV is possible even in an outbreak setting. [16, 26] The Sustainable Development Goal number 3 includes achieving access to affordable, safe, and effective vaccines for all by 2030. [27] Replacing OPV with IPV is essential for the eradication of WPV and VAPP. As we progress towards the certification of the global eradication of polio, ensuring sustainable, reliable, and affordable IPV supply is of paramount importance. The dose sparing and cost reduction characteristics of fractionated doses can contribute to improved IPV access. This review will add to the evidence gathered by other reviews to inform decisions regarding the value of fractionated IPV dosages.
Grassly [28] performed a systematic review and meta-analysis to assess the immunogenicity and effectiveness of 1 or 2 doses of fIPV in routine immunisation. The author found that two fIPV doses administered after 10 weeks of age are likely to provide 80% protection against poliomyelitis. It is now 6-7 years since the literature search was conducted for this review, and new evidence has accumulated since then. [23, 26] In addition, study selection and data extraction were not done in duplicate; increasing the risk of systematic errors in this timely review. [28] It is an indispensable practice in systematic reviews to conduct those critical steps in duplicate, and resolve discrepancies by discussion and consensus or arbitration. [29] In another review, Anand et al. [11] focused on comparing the immunogenicity of two fIPV and one full dose of IPV. They concluded that two fIPV doses are more immunogenic than a single dose. Of note, in both reviews [11, 28] , there is absence of an extensive search of the literature. Grassly searched only the Web of Knowledge collection of databases and Anand and colleagues' search was restricted to the PubMed database. Therefore, there might be other studies that were missed by these reviews that may alter their findings. Vaccine safety and administration are important considerations when deciding on an immunisation schedule. The previous reviews did not evaluate adverse events following administration of different IPV dosages and the devices used to give the intradermal injections. In addition, none of the previous reviews used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method [30] to assess the certainty of the evidence on effects of fIPV. The GRADE approach is now widely adopted as a standard for evidence assessment. [31] We aim to do a systematic review of studies comparing the effects of fractional compared to full dose IPV vaccination. We will evaluate the occurrence of adverse events following vaccination and document the types of administration devices used for the intradermal delivery of fIPV.
OBJECTIVES
The objective of this review is to assess the effects of fractional doses of the inactivated polio vaccine, compared to full doses of the vaccine.
METHODS AND ANALYSIS
Criteria for considering studies for this review Types of studies We will include randomised trials, non-randomised trials, case-control studies, and cohort studies.
Types of participants
Types of intervention
The eligible intervention will be the administration of fractional dose(s) of IPV, while the eligible comparison will be the administration of full dose(s) of the vaccine; irrespective of vaccination schedule or route of administration. Only studies comparing the same number of doses of fractional versus full doses of IPV will be compared.
Types of outcome measures
The primary outcome for this review is immunogenicity, measured using the proportion of participants who sero-converted (as defined by the authors of the included studies) as well as titres of poliovirus-neutralising antibodies for wild poliovirus serotypes 1, 2, and 3; assessed at least four weeks following vaccination.
Our secondary outcomes include adverse events following polio vaccination, vaccine associated paralytic polio, wild poliovirus associated paralytic polio, and mucosal immunity (as defined by the authors). We will also describe the routes and devices used to administer the fractional doses of the vaccine.
Search methods for identification of studies
We will develop a comprehensive search strategy for peer-reviewed and grey literature. We will 
Selection of studies
Two authors (Thandiwe Mashunye and Kopano Dube) will independently screen the search output for potentially eligible studies. We will obtain full texts for all the potentially eligible studies. The two authors will assess these full-text publications for eligibility. We plan to translate full texts of potentially eligible studies which are not written in English before assessing for eligibility. Any disagreements between the two authors regarding study eligibility will be resolved by discussion and consensus. A third author (Duduzile Ndwandwe or Charles Wiysonge) will arbitrate any unresolved disagreements.
Data extraction and management
For each included study, two authors (Thandiwe Mashunye and Kopano Dube) will independently extract the information indicated in Table 1 using a pre-designed and piloted data extraction form. Extracted data will include study, participant, intervention, and outcome characteristics as well as study findings (Table 1) . We will present this information in a table of the characteristics of included studies. Any differences will be resolved through discussion and consensus between the two authors. A third author (Duduzile Ndwandwe or Charles Wiysonge) will be consulted to arbitrate if disagreements persist between the two authors. If there are missing data, we will contact study investigators for the missing information. Methods for generating randomisation sequence, concealing allocation of interventions, and blinding of outcome assessment; number of participants randomised and number with complete outcome data for each outcome; names of outcomes announced in study protocol but not reported in study publication, and other biases.
Participant characteristics
Intervention Definition of fractional dose, manufacturer of vaccine, immunisation schedule (frequency, timing, interval between doses, etc), OPV coadministration, route of administration (intradermal, sub-cutaneous, etc), and types of devices used for administration of the fractional doses (name, manufacturing company, etc).
Comparison
Assessment of risk of bias in included studies
Two authors will independently assess the risk of bias for each included study using the Cochrane Risk of Bias tool for trials [32] and the ROBINS-I tool for non-randomised studies of interventions. [33] For trials, we will assess the risk of bias across seven domains: random sequence generation, allocation concealment, blinding of participants and study personnel, blinding of outcome assessment, completeness of outcome data, selective outcome reporting, and other potential source of bias. For each included study, whether trial or not, we will describe what the study authors reported that they did for each domain and then assign a judgement of low, high, or unclear risk of bias. Differences in judgement will be resolved by discussion and consensus, or arbitration by a third author. Based on these assessments, we will classify each included study as having a low, moderate, or high risk of bias. Each study that receives a judgement of high risk for allocation concealment, blinding of outcome assessment, or completeness of outcome data will be considered to have a high risk of bias. A study that is judged to have low risk of bias for all three domains will be considered to have a low risk of bias. All other studies will be considered to have a moderate risk of bias. We will use these risks of bias data in the GRADE assessments of certainty of evidence, as described below, by downgrading the certainty of the evidence of effects from trials with high risk of bias.
Dealing with missing data
For incomplete or missing data, we will contact corresponding authors to request additional information or clarification. Missing data and dropouts will be reported in the 'risk of bias' table and we will evaluate the impact of missing data on our results. Where possible we will conduct intention to treat analysis (ITT). We will conduct sensitivity analyses whereby missing data are treated as successes or failures (worst-best and best-worst case scenario sensitivity analyses).
Data Synthesis
We will stratify the analyses by the type of study design, type of poliovirus, type of outcome measure, and number of IPV doses given. We will use the risk ratio (RR) and its corresponding 95% confidence interval to summarise data for the following binary outcome measures: seroconversion, adverse events following polio vaccination, vaccine associated paralytic polio, and wild poliovirus associated paralytic polio. For geometric median titres (our only outcome measure with continuous data), we will calculate the mean difference (MD) and its 95% confidence interval when the outcome data are measured on the same scale. Alternatively, if the measurement scale differs, the standardised mean difference (SMD) and its 95% confidence interval will be used.
For each type of poliovirus, we will pool the outcome data from studies with the same design and number of fractional versus full IPV doses administered using the random-effects method of metaanalysis. In studies where there are multiple interventions, we will include pair-wise comparisons that address the objectives of our review as outlined above. To avoid double counts when analysing correlated groups, we will pool the groups together to create a single pair-wise comparison
Assessment of heterogeneity
Initially we will assess for heterogeneity by visually inspecting the forest plots for overlapping confidence intervals. To further evaluate statistical heterogeneity, we will use the χ 2 test of homogeneity; with significance defined at the alpha level of 0.10. We will also use the I 2 statistic to quantify the amount of heterogeneity. [34] We will investigate the causes of statistical heterogeneity using subgroup analyses.
We will define subgroups based on the timing of the first fractional dose, age of administration, number of fractional doses, interval between doses, poliovirus type (1, 2 and 3), type of intradermal injection device, immunisation schedules (OPV containing versus non-OPV schedules), and country income status. [35] Assessment of reporting biases We will reduce possible publication bias by using a comprehensive search strategy. Literature sources will include published, unpublished, and grey literature. To investigate possible publication bias, we will construct funnel plots if there are more than 10 studies included in the metaanalysis. [36] Sensitivity analysis We will perform sensitivity analyses to assess if the effect of fIPV will be affected by risk of bias (by excluding studies with a high risk of bias), study designs (randomised versus non-randomised), and methods of meta-analysis (fixed versus random effects). 
Reporting review findings
The GRADE approach judges the certainty of a body of evidence as high, moderate, low, or very low; through appraising the risk of bias, imprecision, inconsistency and indirectness of study results, and the risk of publication bias. [40, 41] Regarding risk of bias, concerns that will affect our confidence in the evidence of effects are lack of allocation concealment, lack of blinding of outcome assessors, and differential losses to follow-up of more than 10% between fractional and full dose groups. Inconsistency of effects across included studies, for which we find no compelling explanations, will reduce our confidence in the evidence. We will consider indirectness to exist if there are differences between the participants, interventions, comparisons, and outcomes of our review, and those reported in included studies. We do not anticipate that this will be an issue in our planned review. For imprecision, if we obtain pooled estimates of effects with wide confidence intervals (a situation which occurs when included studies have small number of participants and experience few events), we will rate down the certainty of the evidence. Finally, we will downgrade the certainty of evidence of effects of fIPV if our funnel plots show a high likelihood of publication bias.
Patient and public involvement
ETHICS AND DISSEMMINATION
Collection of data for our review does not involve direct contact with human participants. Instead will use published and publicly accessed data. We obtained approval from the University of Cape Town Human Research Ethics Committee (HREC REF: 412/2018). We registered the review in the PROSPERO International Prospective Register of Systematic Reviews (CRD42018092647). The findings of this review will provide policy makers, health workers and donors with evidence for decision making with regards to IPV dosage. In the face of the current shortages, this might improve immediate and long-term access to the vaccine. The results of the review will be published in the University of Cape Town online library and in a peer reviewed journal. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
